Race Oncology Limited (ASX: RAC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Race Oncology Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Race Oncology Limited (ASX: RAC)
Latest News
Share Fallers
Why Meteoric Resources, Race, Temple & Webster, and West African shares are falling today
Share Gainers
Why Bravura, Dateline, Orthocell, and Race Oncology shares are storming higher
Healthcare Shares
Cancer drug developer's shares race to three-year high, up 20% on new research results
Share Gainers
Why Deterra Royalties, DroneShield, Lindian, and Race Oncology shares are rising today
Healthcare Shares
Guess which ASX All Ords share is up 9% on 'important milestone'
Healthcare Shares
Why did this ASX All Ords healthcare share just rocket 28%?
Share Gainers
3 ASX biotech shares rocketing 10% to 26% on BIG news!
Healthcare Shares
ASX IPO watch: Aspiring healthcare stock has attracted former Macquarie CEO to invest
Healthcare Shares
2 ASX healthcare shares having a stellar run today
Share Gainers
Why Pinnacle, PWR, Race Oncology, and Vulcan shares are flying today
Earnings Results
Two up, one down: ASX healthcare stocks split after FY24 results
Healthcare Shares
2 ASX healthcare shares outperforming on big news
Frequently Asked Questions
-
No, Race Oncology does not pay dividends at this time.
-
Sydney-headquartered Race Oncology Ltd listed on the ASX on 13 July 2016.
RAC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Race Oncology Limited
Race Oncology Ltd (ASX: RAC) is a clinical-stage global biotechnology company focused on cancer care.
Race’s lead asset, bisantrene, is a small-molecule anthracene chemotherapeutic. It has demonstrated anti-cancer and cardio-protection effects in 46 clinical trials and around 70 peer-reviewed publications.
The company is now taking its next-generation bisantrene to new fields of cancer treatment. It is initially focusing on two areas of unmet need: metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML).
As part of its business strategy and clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway. This follows independent research describing bisantrene as the most potent inhibitor of fat mass and obesity-associated protein (FTO). Dysregulation of RNA (or the over-expression of FTO) has been shown to be a driver of a diverse range of cancers. Race and its partners are now in pre-clinical studies to explore the synergies and impact of bisantrene on FTO regulation.
